Design and synthesis of novel p38alpha MAP kinase inhibitors: discovery of pyrazole-benzyl ureas bearing 2-molpholinopyrimidine moiety.
Article Details
- CitationCopy to clipboard
Arai T, Ohno M, Inoue H, Hayashi S, Aoki T, Hirokawa H, Meguro H, Koga Y, Oshida K, Kainoh M, Suyama K, Kawai H
Design and synthesis of novel p38alpha MAP kinase inhibitors: discovery of pyrazole-benzyl ureas bearing 2-molpholinopyrimidine moiety.
Bioorg Med Chem Lett. 2012 Aug 1;22(15):5118-22. doi: 10.1016/j.bmcl.2012.05.095. Epub 2012 Jun 12.
- PubMed ID
- 22749282 [ View in PubMed]
- Abstract
The discovery that pyrazole-benzyl urea derivatives bearing a 2-molpholinopyrimidine moiety are novel p38alpha inhibitors is described. A comparative view of the binding modes of SB-203580 and BIRB-796 by structural alignment of two X-ray co-crystal structures was utilized to identify this novel series. Modification of the benzyl group led to compound 2b, a highly potent p38alpha inhibitor. In in vivo studies, 2b inhibited the production of tumor necrosis factor-alpha in lipopolysaccharide-treated mouse in a dose-dependent manner. Furthermore, the results of a 5-day repeated oral dose toxicity study suggest that 2b has low hepatotoxicity.
DrugBank Data that Cites this Article
- Binding Properties
Drug Target Property Measurement pH Temperature (°C) Doramapimod Mitogen-activated protein kinase 14 IC 50 (nM) 10 N/A N/A Details